Expert Analysis

CME

Key Studies in Leukemias: Independent Conference Coverage of ASH 2020

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: February 12, 2021

Expiration: February 11, 2022

Jorge Cortes
Jorge Cortes, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed

At the virtual ASH 2020 annual meeting, new clinical data were reported in the settings of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). In this expert analysis module, Jorge Cortes, MD, and Eunice S. Wang, MD, review and discuss the clinical implications of key findings for these diseases that were presented at the meeting.

Please note that the slide thumbnails embedded in this activity link to short PowerPoint slidesets, each focused on the specific study of interest. The slides for the studies covered in this activity may be downloaded by clicking on any of the thumbnails within the activity.

CCO plans to measure the educational impact of this activity. Some of the questions in this activity will be asked twice: once at the beginning and then once again after the specific discussion of the relevant information. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with leukemia do you provide care for in a typical month?

In your current practice, which of the following strategies would you choose for an elderly patient with AML treated with CC-486 maintenance therapy who experiences early relapse (10% increased blasts) after initial CR?

When presenting new data reported at the ASH 2020 meeting to your clinical team, which of the following would you tell them is TRUE about asciminib, an investigational agent being evaluated in trials enrolling patients with chronic-phase CML?

In your current practice, which of the following treatment strategies with ponatinib would you recommend for a patient with T315I-mutated CP CML and controlled hypertension who progressed on 2 previous BCR-ABL TKIs?